Acumen Pharmaceuticals, Inc. ABOS NASDAQ

Acumen Pharmaceuticals, Inc. (ABOS) reported total assets of $122.83M and total liabilities of $52.4M for fiscal year 2025, resulting in total equity of $70.43M.

The company held $116.87M in cash and short-term investments. Total debt stood at $31.31M, with net debt of $-22.68M. The Debt-to-Equity (D/E) ratio was 0.44 (conservative).

Current ratio is 4.07, indicating strong short-term liquidity. Interest coverage is -29.3x (weak).

Criteria supported by this page:

• HEALTH (67/100, Partial) — some metrics are adequate but not all reach ideal thresholds
• MOAT (28/100) — Total assets $122.83M and equity $70.43M support the company's competitive scale
• VALUE (100/100) — Debt-to-Equity 0.44 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 50/100 with 2/7 criteria passed.

TERN

Terns Pharmaceuticals, Inc.

$52.71

+0.06%

DAWN

Day One Biopharmaceuticals, Inc.

$21.47

+0.05%

AMLX

Amylyx Pharmaceuticals, Inc.

$17.12

+1.18%

INZY

Inozyme Pharma, Inc.

$4.00

+0.25%

MREO

Mereo BioPharma Group plc

$0.34

+2.98%

XFOR

X4 Pharmaceuticals, Inc.

$4.33

+3.10%

HOOK

HOOKIPA Pharma Inc.

$1.11

-1.34%

LLY

Eli Lilly and Company

$905.13

-1.88%